Evidence map›Paper›PMID 38725070›Full record

ArticleExperimental hematology & oncology2024

NK cell transfer overcomes resistance to PD-(L)1 therapy in aged mice.

Junlei Hou, Shuanglong Xie, Jianbao Gao, Tao Jiang, Enjian Zhu, Xuezhi Yang, Zheng Jin, Haixia Long, Anmei Zhang, Fei Yang and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Experimental hematology & oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Review
  6. The spleen-brain axis in Alzheimer's disease and related dementias: Integrating immune and metabolic regulation.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Junlei Hou *Institute of Cancer, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China.
Shuanglong Xie *Institute of Cancer, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China.
Jianbao Gao *Institute of Cancer, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China.
Tao JiangShanghai Pulmonary Hospital, Shanghai, 200082, China.
Enjian ZhuInstitute of Cancer, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China.
Xuezhi YangInstitute of Cancer, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China.
Zheng JinInstitute of Cancer, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China.
Haixia LongInstitute of Cancer, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China.
Anmei ZhangInstitute of Cancer, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China.
Fei YangInstitute of Cancer, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China.
Lujing WangInstitute of Cancer, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China.
Haoran ZhaDepartment of Oncology, PLA Rocket Force Characteristic Medical Center, Beijing, 100088, China.
Qingzhu JiaInstitute of Cancer, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China. qingzhu.jia@tmmu.edu.cn.
Bo ZhuInstitute of Cancer, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China.
Xinxin WangInstitute of Cancer, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China.

Funding

National Natural Science Foundation of China 81925030National Natural Science Foundation of China 82273213National Nature Science Foundation of China 81821003
6 · The paper itself

Abstract

backgroundCancer is the leading cause of death among older adults. Although the integration of immunotherapy has revolutionized the therapeutic landscape of cancer, the complex interactions between age and immunotherapy efficacy remain incompletely defined. Here, we aimed to elucidate the relationship between aging and immunotherapy resistance.

methodsFlow cytometry was performed to evaluate the infiltration of immune cells in the tumor microenvironment (TME). In vivo T cell proliferation, cytotoxicity and migration assays were performed to evaluate the antitumor capacity of tumor antigen-specific CD8

resultsWe found that elderly patients with advanced non-small cell lung cancer (aNSCLC) aged ≥ 75 years exhibited poorer progression-free survival (PFS), overall survival (OS) and a lower clinical response rate after immunotherapy. Mechanistically, we showed that the infiltration of NK cells was significantly reduced in aged mice compared to younger mice. Furthermore, the aged NK cells could also suppress the activation of tumor antigen-specific CD8

conclusionOur findings revealed the decreased sensitivity of elderly patients to immunotherapy, as well as in aged mice. This may be attributed to the reduction of NK cells in aged mice, which inhibits CD103

Indexed as

AgingCancer immunotherapyDendritic cellsNatural killer cells

Identifiers

PMID38725070
PMCPMC11080179

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.